Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage criteria, and coding for sacral nerve stimulation (SNS/SNM) to treat urinary and fecal incontinence, non-obstructive urinary retention, and related pelvic floor dysfunction for Blue Cross Blue Shield North Carolina members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Sacral Nerve Stimulation
inv-01: Trial period (Urinary)
Covered when ALL of the following are met:
Trial period may be percutaneous nerve stimulation or a temporarily implanted lead.
inv-02: Permanent implantation (Urinary)
Covered when ALL of the following are met:
Policy history: trial duration requirement revised over time (≥2 weeks → ≥1 week → ≥48 hours).
inv-03: Fecal incontinence
Covered when ALL of the following are met:
Trial period may be percutaneous nerve stimulation or a temporarily implanted lead.
Successful percutaneous test stimulation defined historically as ≥50% improvement; trial duration requirement revised over time to ≥48 hours.
inv-04: Initial trial and permanent implantation criteria
Covered when ALL of the following are met for a trial period and for permanent implantation respectively:
Trial methods include PNE (4–7 days) or staged/tined lead testing; documentation of therapies tried and duration should be retained.
Provider documentation of trial response and prior conservative therapy required for medical necessity determination.
Historical policy language retained to reflect prior criteria and trial-duration revisions.
The following applications of sacral nerve neuromodulation/stimulation are considered investigational and not covered: treatment of stress incontinence; treatment of urge incontinence when secondary to a neurologic condition (examples listed include detrusor hyperreflexia, multiple sclerosis, spinal cord injury, and other chronic voiding dysfunction); patients with mechanical urethral obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture; and conditions that have responded to behavioral or pharmacologic interventions. The policy also designates sacral nerve neuromodulation as investigational for the treatment of chronic constipation and chronic pelvic pain.
For fecal incontinence coverage, specific exclusions are noted: conditions related to an anorectal malformation (for example congenital anorectal malformation), defects of the external anal sphincter greater than 60 degrees, visible sequelae of pelvic radiation, active anal abscesses or fistulae, and chronic inflammatory bowel disease are cited as exclusions. The policy also indicates that fecal incontinence related to certain neurologic conditions is not appropriate for coverage in some contexts.
The policy explicitly states that sacral nerve neuromodulation is considered investigational (not covered) for the treatment of chronic constipation and for chronic pelvic pain due to insufficient and inconsistent evidence of clinical benefit.
Policy revision history documents movement of earlier statements about inadequate evidence for certain indications into the investigational/not‑covered section: prior language regarding limited data for InterStim® in patients with chronic pelvic pain, constipation, and some fecal incontinence contexts was relocated to the When Not Covered section during the 2/2/10 update; subsequent updates refined fecal incontinence criteria and trial requirements over time.
Applicable Procedure, Supply, and Diagnosis Codes
| R15.0 | |
| R15.1 | |
| R15.2 | |
| R15.9 | |
| R32 | |
| R33.0 | |
| R33.8 | |
| R33.9 | |
| R39.14 | |
| N39.3 |
| 787.60 | Diagnosis code (ICD-9) listed in Billing/Coding section |
| 787.61 | Diagnosis code (ICD-9) listed in Billing/Coding section |
| R15.9 | ICD-10 diagnosis code listed in Billing/Coding section |
| R15.0 | ICD-10 diagnosis code listed in Billing/Coding section |
Provider Requirements, Prior Authorization, and Documentation
Prior authorization / coverage determination may be required
Prior authorization/coverage determination may be required for sacral nerve neuromodulation procedures and supplies listed in the policy; BCBSNC may request medical records to determine medical necessity.
Trial stimulation demonstrating ≥50% improvement required before permanent implant
A trial stimulation (percutaneous nerve stimulation or temporarily implanted lead) demonstrating at least 50% improvement in symptoms is required before permanent implantation; the trial must demonstrate that improvement over a period of at least 48 hours.
- Successful trial defined as ≥50% improvement in symptoms.
- Trial duration requirement revised over time and currently specified as at least 48 hours.
Failure of ≥2 conventional therapies required before trial
Patients must have documented failure or intolerance to at least two conventional therapies (behavioral, pharmacologic for sufficient duration, and/or surgical corrective therapy as appropriate) prior to trial stimulation.
- Conventional therapies include behavioral training (bladder training, prompted voiding, pelvic muscle exercises), pharmacologic treatment for a sufficient duration, and/or surgical corrective therapy.
Document failure/intolerance to behavioral, pharmacologic, and/or surgical therapies
Documentation must show failure or intolerance to conservative therapies—behavioral training, pharmacologic treatment, and/or surgical corrective therapy—before consideration of sacral nerve neuromodulation.
- Conservative therapies cited include dietary modification and bulking agents for fecal incontinence as applicable.
- Pharmacologic therapy must have been given for a sufficient duration to fully assess efficacy.
Medical records may be requested; letters alone insufficient unless complete
BCBSNC may request medical records to determine medical necessity; letters of support/explanation are helpful but are not sufficient unless they include all specific information needed for the medical necessity determination.
- When medical records are requested, include all specific clinical information referenced in the policy (diagnosis, documentation of prior therapies and durations, trial stimulation results and duration, surgical candidacy).
- Letters alone will not substitute for detailed medical records unless they contain all required information.
Documentation review may lead to denial if required records are not provided
BCBSNC may review submitted records to determine medical necessity and may deny coverage if requested documentation is not provided.
- Failure to provide the requested medical records or the specific information needed for medical necessity review can trigger denial of the request.
- Requested records should include documentation of diagnoses, prior conservative therapies and durations, trial stimulation success (≥50%) and trial duration, and surgical candidacy.
Respond to documentation requests promptly or risk denial
BCBSNC may issue documentation requests for medical records to make a medical necessity determination; lack of the requested documentation may result in denial.
- Ensure timely submission of complete medical records when requested, including trial stimulation data and documentation of prior therapy failures.
- Letters of support are only sufficient when they contain all specific information needed for the determination.
Medical records must contain specific information needed for medical necessity review
If medical records are requested, they must include the specific information necessary for a medical necessity determination (diagnosis, details of prior conservative therapies and durations, trial stimulation results and duration, and surgical candidacy); letters alone are insufficient unless they include all required details.
- Include evidence of trial stimulation success defined as ≥50% improvement and the duration of the trial (currently at least 48 hours).
- For fecal incontinence cases, include episode frequency, duration of symptoms, and exclusionary conditions (e.g., anorectal malformation, recent rectal surgery).
Definitions and Key Concepts
Background on Sacral Nerve Stimulation
Sacral nerve stimulation (SNS), also referred to as sacral nerve neuromodulation (SNM), is an implanted neuromodulation therapy that targets the sacral nerve roots—most commonly the S3 nerve root—to modulate neural control of bladder and rectal function. It is intended to alter aberrant reflex pathways to reduce symptoms of urge incontinence, urgency‑frequency, nonobstructive urinary retention, overactive bladder, and selected cases of chronic fecal incontinence. A diagnostic trial stimulation (either percutaneous nerve evaluation or a temporarily implanted lead/staged approach) is used to assess symptom response prior to permanent implantation; historically this trial requires demonstration of at least 50% improvement in symptoms over the required trial duration.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.